Evidence map›Paper›PMID 38365480›Full record

ArticleVaccine2024

Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.

Michael Rockson Adjei, Amos Longsignikuu, Ibrahim Saeed Iddris, Thomas Nang Suuri, Byrite Asamoah, Michael Okoye, Janet Vanessa Baafi, Chrysantus Kubio, Sally-Ann Ohene, Martin Peter Grobusch

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 6 countries.

Michael Rockson AdjeiCenter of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Iocation AMC, University of Amsterdam, Amsterdam, the Netherlands; World Health Organization, Country Office, Accra, Ghana. Electronic address: m.r.adjei@amsterdamumc.nl.
Amos LongsignikuuGhana Health Service, Regional Health Directorate, Savannah Region, Damongo, Ghana.
Ibrahim Saeed IddrisGhana Health Service, Regional Health Directorate, Savannah Region, Damongo, Ghana.
Thomas Nang SuuriGhana Health Service, Regional Health Directorate, Savannah Region, Damongo, Ghana.
Byrite AsamoahSynlab, Accra, Ghana.
Michael OkoyeAcacia Health Insurance, Accra, Ghana.
Janet Vanessa BaafiGhana Health Service, District Health Directorate, Sunyani West, Odumase, Ghana.
Chrysantus KubioGhana Health Service, Regional Health Directorate, Savannah Region, Damongo, Ghana.
Sally-Ann OheneWorld Health Organization, Country Office, Accra, Ghana.
Martin Peter GrobuschCenter of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Iocation AMC, University of Amsterdam, Amsterdam, the Netherlands; Institute of Tropical Medicine, and German Center of Infectious Diseases (DZIF), University of Tuebingen, Tuebingen, Germany; Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Centre de Recherches Médicales En Lambaréné (CERMEL), Lambaréné, Gabon; Masanga Medical Research Unit, Masanga, Sierra Leone.
Ghana Health Service · GHCentre de Recherche Médicales de Lambaréné · GASynlab Czech (Czechia) · CZ

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionGhana witnessed an outbreak of measles in 2022 following the COVID-19 pandemic, and Savannah Region was among the regions severely impacted. The objective of this study was to conduct trend analysis of measles case incidence and measles-rubella (MR) vaccination coverage in the Savannah Region to identify gaps and propose remedial actions to mitigate future outbreaks of vaccine preventable diseases (VPDs).

methodsAnalysis of measles surveillance and measles-rubella vaccination data for 2018-2022 was conducted to assess relationship between immunization coverage and measles case incidence. Data were extracted from the District Health Information Management System (DHIMS) platform and loaded into Microsoft Excel 16.0 spreadsheet for analysis. Coverages for first (MR1) and second (MR2) doses of measles-rubella vaccination, dropout rates, and measles incidence (per 100,000) were calculated.

resultsThe coverage trend for both vaccine doses followed similar trajectories, increasing from 2018 to a peak in 2019, and declining sequentially thereafter to the lowest (for the study period) in 2022. Generally, MR1/MR2 dropout rate was high across all districts during the entire study period. The regional incidence of confirmed measles rose sharply from less than 1/1,000,000 in 2018-2021 to 94 in 2022. Wide variations in vaccination coverage and dropout rates were observed among the districts. There was moderate to fairly strong negative correlation between MR vaccination coverage and measles case incidence.

conclusionsThe MR vaccination coverage in the Savannah Region declined probably due to pre-existing weaknesses in the immunization programme accentuated by impact of the COVID-19 pandemic. The lowered population immunity likely contributed to occurrence of the measles outbreak in 2022. Pragmatic actions are needed to catch-up on missed children, restore coverage to pre-pandemic levels, and strengthen the immunization programme as part of global efforts towards achieving the Immunization Agenda 2030 (IA2030) trajectory.

Indexed as

COVID-19MeaslesRubellaChildGhanaHumansInfantMeasles VaccinePandemicsRubella VaccineSecondary Data AnalysisVaccinationVaccination CoverageMeasles VaccineRubella VaccineDropout rateGhanaMeasles outbreakMeasles-rubella vaccineSavannah RegionVaccination coverage

Identifiers

PMID38365480
PMCPMC11080765
OpenAlexW4391887114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.